CD40 anticorps
Aperçu rapide pour CD40 anticorps (ABIN6941471)
Antigène
Voir toutes CD40 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Aucune reactivité croisée
- Humain
-
Purification
- Purified by Protein A/G
-
Immunogène
- Purified recombinant Mouse CD40 fusion protein
-
Isotype
- IgG2a kappa
-
-
-
-
Indications d'application
-
Positive Control: MPBMC's. Spleen, Thymus or Lymph Node.
Known Application: Functional Studies (Order Antibody without BSA & Azide); Flow Cytometry (0.5-1ug/million cells in 0.1ml); Immunofluorescence (0.5-1ug/ml)Optimal dilution for a specific application should be determined.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 200 μg/mL
-
Buffer
- 10 mM PBS with 0.05 % BSA & 0.05 % azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- 4 °C,-80 °C
-
Stockage commentaire
- Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
-
Date de péremption
- 24 months
-
-
- CD40
-
Autre désignation
- CD40
-
Sujet
- Upon binding to its ligand CD154, CD40 acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other APCs. CD40 plays roles in B cell activation, differentiation, proliferation and Ig isotype switching as well as dendritic cell maturation. FGK4.5 can be used for blocking of CD40/CD154 interaction and forin vitroandin vivoactivation of CD40 expressing APCs. This MAb is shown to indirectly activate natural killer (NK) cells, producing significant antitumor and anti-metastatic effects. Effective in boosting immune responses against infectious agents and can potentially be used to treat chronic autoimmune inflammatory processes.
-
Poids moléculaire
- 48kDa
-
ID gène
- 21939
-
UniProt
- P27512
-
Pathways
- Signalisation NF-kappaB, Cellular Response to Molecule of Bacterial Origin, M Phase, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints
Antigène
-